Long-term correction of copper metabolism in Wilsons disease mice with AAV8 vector delivering truncated ATP7B
This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease
Group III (10 patients) received oral placebo capsules (as a control) once daily for 4 weeks
Retatrutide produces greater weight loss at every comparable timepoint, despite using a lower maximum dose (12 mg versus 15 mg)
On the skin side, pallor, a yellowish tinge, dryness, hyperpigmented patches (particularly on the hands or face), and mouth or tongue soreness are classic signs
Rather than simply masking signs of aging, the peptide appears to support some of the biological systems that influence skin health beneath the surface